IDEAYA Biosciences, Inc. (IDYA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $10.00K; Additional Paid in Capital, Common StockUSD $2.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.67M; Retained Earnings (Accumulated Deficit)USD $-947.53M.
- 2026-03-31: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $1.77B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-494.00K; Retained Earnings (Accumulated Deficit)USD $-835.08M.
- 2025-12-31: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $1.76B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.27M; Retained Earnings (Accumulated Deficit)USD $-736.54M.
- 2025-09-30: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $1.74B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.05M; Retained Earnings (Accumulated Deficit)USD $-653.27M.
IDEAYA Biosciences, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.00K | $2.15B | $-1.67M | $-947.53M | $1.20B | 3 month · $16.66M 6 month · $31.19M | 3 month · $141.00M 6 month · $141.00M |
| 2026-03-31 | $9.00K | $1.77B | $-494.00K | $-835.08M | $937.27M | 3 month · $14.54M | (m) |
| 2025-12-31 | $9.00K | $1.76B | $2.27M | $-736.54M | $1.02B | 12 month · $46.12M | (m) |
| 2025-09-30 | $9.00K | $1.74B | $2.05M | $-653.27M | $1.09B | 3 month · $12.22M 9 month · $34.32M | (m) |
| 2025-06-30 | $9.00K | $1.73B | $1.52M | $-772.51M | $959.65M | 3 month · $11.87M 6 month · $22.11M | (m) |
| 2025-03-31 | $9.00K | $1.72B | $1.58M | $-695.02M | $1.02B | 3 month · $10.24M | (m) |
| 2024-12-31 | $9.00K | $1.68B | $812.00K | $-622.84M | $1.06B | 12 month · $34.75M | 12 month · $9.40M |
| 2024-09-30 | $9.00K | $1.67B | $3.84M | $-492.53M | $1.18B | 3 month · $9.21M 9 month · $25.26M | 3 month · $9.40M 9 month · $9.40M |
| 2024-06-30 | $8.00K | $1.37B | $-1.42M | $-440.71M | $931.66M | 3 month · $9.73M 6 month · $16.05M | (m) |
| 2024-03-31 | $7.00K | $1.32B | $-923.00K | $-387.94M | $935.31M | 3 month · $6.31M | (m) |
| 2023-12-31 | $7.00K | $968.88M | $562.00K | $-348.36M | $621.09M | 12 month · $18.49M | 12 month · $42.18M |
| 2023-09-30 | $6.00K | $823.20M | $-750.00K | $-314.41M | $508.05M | 3 month · $5.30M 9 month · $13.69M | 9 month · $35.13M |
| 2023-06-30 | $6.00K | $789.75M | $-1.18M | $-286.97M | $501.61M | 3 month · $4.73M 6 month · $8.39M | 3 month · $35.13M 6 month · $35.13M |
| 2023-03-31 | $5.00K | $594.25M | $-1.41M | $-259.04M | $333.81M | 3 month · $3.66M | (m) |
| 2022-12-31 | $5.00K | $587.72M | $-2.87M | $-235.40M | $349.45M | 12 month · $11.63M | (m) |
| 2022-09-30 | $5.00K | $583.97M | $-4.00M | $-211.20M | $368.77M | 3 month · $3.00M 9 month · $8.65M | (m) |
| 2022-06-30 | $4.00K | $485.76M | $-3.63M | $-212.82M | $269.32M | 3 month · $3.04M 6 month · $5.65M | (m) |
| 2022-03-31 | $4.00K | $482.23M | $-2.80M | $-190.76M | $288.67M | 3 month · $2.60M | (m) |
| 2021-12-31 | $4.00K | $478.97M | $-712.00K | $-176.75M | $301.51M | 12 month · $8.24M | (m) |
| 2021-09-30 | $4.00K | $476.21M | $-50.00K | $-158.54M | $317.63M | 3 month · $2.20M 9 month · $6.17M | (m) |
| 2021-06-30 | $3.00K | $387.21M | $-4.00K | $-146.95M | $240.26M | 3 month · $2.06M 6 month · $3.98M | (m) |
| 2021-03-31 | $3.00K | $369.13M | (m) | $-136.01M | $233.12M | 3 month · $1.92M | (m) |
| 2020-12-31 | $3.00K | $325.25M | $7.00K | $-126.99M | $198.27M | 12 month · $3.61M | (m) |
| 2020-09-30 | $3.00K | $317.24M | $35.00K | $-121.85M | $195.43M | 3 month · $981.00K 9 month · $2.56M | (m) |
| 2020-06-30 | $3.00K | $288.92M | $57.00K | $-116.92M | $172.06M | 3 month · $824.00K 6 month · $1.58M | (m) |
| 2020-03-31 | $2.00K | $193.63M | (m) | $-104.53M | $89.10M | 3 month · $758.00K | (m) |
| 2019-12-31 | $2.00K | $192.82M | $65.00K | $-92.49M | $100.40M | 12 month · $2.17M | (m) |
| 2019-09-30 | $2.00K | $192.04M | $78.00K | $-81.71M | $110.41M | 3 month · $518.00K 9 month · $1.45M | (m) |
| 2019-06-30 | $2.00K | $191.31M | $37.00K | $-70.74M | $120.61M | 3 month · $548.00K 6 month · $931.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | $-58.06M | 3 month · $383.00K | (m) |
| 2018-12-31 | (m) | $1.60M | $-31.00K | $-50.52M | $-48.95M | 12 month · $950.00K | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $-40.74M | 3 month · $287.00K 9 month · $625.00K | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-28.05M | 3 month · $226.00K 6 month · $338.00K | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-21.31M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $-15.74M | 12 month · $136.00K | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $-4.13M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |